Pareto Biotechnologies
San Francisco
About Pareto Biotechnologies
Pareto Biotechnologies has pioneered development of a revolutionary synthetic biology platform that produces naturally derived, high value “designer molecules.” Pareto’s technology is the result of over a decade of academic and private sector research and intellectual property focused on one particular polyketide pathway. Building on Dr. Joe Noel’s groundbreaking research at the Salk Institute, this pathway – previously dismissed as the “poor man’s pathway” – is the foundation of Pareto’s platform, capable of generating known products and novel molecules.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Last round: Series Unknown (May 2015)
- Website: paretobio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Chemical, Health Care, Renewable Energy
Social Profiles
Canonical: https://fsome.com/organization/pareto-biotechnologies-2456001 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.